America's prescription-drug prices are not proven to be the world's lowest.
Available international comparisons contradict the sweeping claim, even though some generic drugs are cheaper in the United States.
Confidence in FICTION verdict
Available international price comparisons establish that average US prescription-drug prices are the lowest among peer countries.
Prescription-drug prices are difficult to reduce to a slogan. They vary by product, patent status, insurance coverage and whether researchers measure posted or net prices. The strongest available peer-country studies do not support describing America as the cheapest market overall.
Research commissioned by HHS and carried out by RAND examined international data and found that US prices across brand and generic drugs averaged roughly 2.78 times comparator-country prices in 2022. Brand-name medicines had particularly large gaps, while unbranded generics could be cheaper in the United States. This is the evidence against the blanket lowest-price claim.
The comparison is not a real-time census of every pharmacy in 2026. New price negotiations may change specific drugs. The appropriate verdict is that the sweeping claim is not established by the reliable comparative record—not that every American prescription costs more than its foreign equivalent.
What this could mean.
- Why this verdict matters
- Drug price rhetoric shapes expectations of patients, insurers and policymakers.
- Potential consequences
Patients may overestimate how broad announced discounts will be.
Drug-by-drug comparisons can reveal where reform has actually worked.
Policy debates should distinguish brand medicines from generic markets.
The assessment.
- Claim being checked
- Available international price comparisons establish that average US prescription-drug prices are the lowest among peer countries.
- Evidence period
- Evidence available through October 15, 2026, with most detailed comparative research based on 2022 transactions.
- Why we assign this confidence score
- A US Department of Health and Human Services commissioned comparison found US prices for all prescription drugs were about 2.78 times those in peer OECD markets, with important generic-drug exceptions.
- What could change the verdict
- Historical cross-country averages cannot prove every 2026 transaction price; rebates, drug mixes and new pricing policies vary across markets.
The evidence.
- Comparing Prescription Drugs in the U.S. and Other Countries ↗HHS Assistant Secretary for Planning and Evaluation · 2024-01-31
- International Prescription Drug Price Comparisons: 2022 data ↗National Library of Medicine / ASPE · 2024